Schueren Robert Alan

About Schueren Robert Alan

Robert Alan Schueren is an American life sciences and medical diagnostics executive best known for his work at Natera, Inc., where he served as Chief Operating Officer. Public governance filings show that he held the COO role starting in January 2019, after joining Natera from IntegenX, a biotechnology company where he served as Chief Executive Officer and President from March 2013 to January 2019. His career reflects deep experience leading innovative growth-stage businesses, with a background spanning operations, commercial execution, and executive management in biotechnology and diagnostics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1604821/000104746920002362/a2241336zdef14a.htm?utm_source=openai)) At Natera, a Nasdaq-listed company focused on genetic testing and molecular diagnostics, Schueren played an important operating role during a period of expansion and organizational scaling. As COO, he was involved in helping coordinate core operational functions supporting the company’s growth in the U.S. diagnostics market and the broader commercialization of its product portfolio. Public filings also indicate that his responsibilities gradually transitioned during 2023 as part of a planned succession process, which suggests an orderly reduction in duties rather than an abrupt exit. ([prnewswire.com](https://www.prnewswire.com/news-releases/natera-appoints-steve-chapman-ceo-and-robert-schueren-coo-matthew-rabinowitz-moves-to-executive-chairman-300772050.html?utm_source=openai)) Before Natera, his tenure as CEO and President of IntegenX highlights experience at the top of a biotechnology company, indicating familiarity with leading multidisciplinary teams, scaling operations, and supporting companies through growth and strategic transition. Based on the public sources reviewed, his most notable contributions appear to be operational leadership and executive transition management in diagnostics and biotech businesses. The available materials do not provide enough verified detail to confidently attribute additional major roles, company leadership positions, or specific strategic decisions, so it is best to keep the profile conservative and generic where uncertainty remains. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1604821/000104746920002362/a2241336zdef14a.htm?utm_source=openai))